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Practice Matters: Adult Vaccination Recommendations 
Vaccines are one of the most important primary prevention services to help combat 
infectious disease and improve health throughout the lifespan (U.S. Department of Health and 
Human Services [HHS], 2021a). Since most vaccines are recommended and scheduled for the 
pediatric population, adult vaccinations for those over the age of 18 years are often a second 
thought. With the onset of the global 2019 coronavirus (COVID-19) pandemic, adult vaccination 
needs have reemerged in mainstream discussion. Faith Community Nurses (FCN) are an important 
resource for all those within their faith community. FCN promote care of the body, mind, and spirit 
while promoting health and wellness through education, screenings, and basic health services 
(Mock, 2017). FCN have successfully implemented various health promotion programs for 
diabetes, hypertension, obesity, injury prevention and have increased vaccination rates along with 
promotion of Healthy People 2020 initiatives (Bangurah et al., 2017; Copper et al., 2015; Long, 
2020; Pappas, 2012; Pappas & King, 2014; Willis & Krichten, 2012). FNC can serve as an 
important resource for education, screening, and identification of adults not up to date on 
recommended vaccinations. Therefore, FCN must be aware of current recommendations and 





After reading this article, the FCN will: 
1. Be aware of the importance of vaccinations for adults over the age of 18 years for 
primary prevention of infectious disease. 
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2. Be able to discuss the Centers for Disease and Prevention (CDC) vaccination 
recommendations for adults over the age of 18 years in the United States.  
3. Be able to discuss vaccine contraindications and identify potential adverse effects. 
 
Background 
Pre-existing health conditions, travel, personal lifestyle, and work environments along with 
waning protection received from childhood vaccinations can leave adults vulnerable to preventable 
diseases (CDC, 2021a). Even though adults are at risk for serious illness, hospitalization, and death 
from vaccine-preventable diseases, immunization rates in the United States (U.S.) remain low and 
are well below governmental targets (Lu et al., 2021). Significant disparities for vaccinations exist 
by race, ethnicity, age, and other social and geographical determinants increasing the risks of 
infectious disease to individuals, communities, and the nation (HHS, 2021a). In addition to existing 
disparities, increasing anti-vaccine ideals and mistrust have led to vaccination refusals furthering 
preventable disease outbreaks. The COVID-19 pandemic, along with the development of new 
vaccines and vaccine technology, has spotlighted the need for open discussion and education to 
improve public confidence and trust in vaccine safety (HHS, 2021a).  
The Centers for Disease Control and Prevention (CDC) (2021a) recommends adult 
vaccinations based on several individual variables that are updated and published annually. 
Recommendations should include the considerations of age (see Figure 1), previous vaccination 
status, underlying medical conditions and review of special situations (see Figure 2) (CDC, 
2021b). Best practice guidelines and recommendations for immunizations are updated 
approximately every three to five years by The Advisory Committee on Immunization Practices 
(ACIP) General Recommendations Work Group (GRWG) (CDC, 2019a). Recommendations are 
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based on the most current scientific and expert opinions from healthcare providers and public 
health officials (CDC, 2019a). The high safety standards established in the U.S. for vaccine 
approval and ongoing monitoring are rigorous with many legal protections in place to ensure the 
safety, quality, and effectiveness of vaccines (HHS, 2021b). Vaccines go through extensive testing 
and evaluation by the Food and Drug Administration (FDA) prior to receiving recommendation 
from the CDC.  
 
Figure 1 
Recommended Adult Vaccinations by Age 
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Figure 2 
Recommended Adult Vaccinations by Medical Condition or Other Indications 
 
Note. CDC, 2021b. Recommended adult immunization schedule by medical condition and other 




Current general administration recommendations for adult vaccines include the following: 
(1) administer recommended vaccines even if vaccination status is unknown and (2) additional 
doses or restarts to series-based vaccines should not be administered even if there is an extended 
time between doses (CDC, 2021a). Severe allergic reaction to a previous dose of any vaccine is a 
contraindication to a second dose of the same vaccine, and the individual should consult with their 
health care provider. Severe allergic reactions can occur with any vaccine regardless of prior 
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reaction; therefore, providers administering vaccines must be aware of signs of reaction and 
emergency treatment plans. In most cases, individuals with a mild illness, such as a cold, may be 
vaccinated. Individuals who are moderately or severely ill may need to wait until they are 
recovered from their illness before receiving vaccinations and should consult with their health care 
provider. Common side effects are generally mild, of short duration, and include redness or 




Inactivated (IIV) or recombinant (RIV4) influenza (flu) vaccine is recommended annually 
as a one-time injection for all adults without contraindications with any licensed, age-appropriate 
flu vaccine (CDC, 2021a). Live attenuated (LAIV4) vaccines are recommended for those less than 
50 years of age, and high dose formulation is recommended for those 65 years or older. In addition 
to preventing the flu, the vaccine decreases the risk of severe illness, hospitalization, and illness-
induced heart and lung problems. Individuals who developed Guillain-Barré syndrome within six 
weeks following a previous dose of influenza vaccine should not be vaccinated unless benefits 
outweigh risks. Egg allergy is no longer considered an absolute contraindication to flu vaccine. 
Individuals with mild egg allergy, including hives, may receive an annual flu vaccine. Individuals 
with severe egg allergy, including anaphylaxis or angioedema, may receive a flu vaccine 
administered in a medical setting with personnel capable of identifying and treating severe allergic 
reactions. Live attenuated vaccines should not be administered to individuals who are 
immunocompromised or are a close contact/caregiver for individuals who are severely 
immunocompromised, pregnant, or have asplenia, cranial cerebrospinal fluid/oropharyngeal 
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communications, or cochlear implant. Additionally, individuals who have taken oseltamivir or 
zanamivir within 48 hours, peramivir within 5 days, or baloxavir within 17 days should not receive 
live attenuated flu vaccine. The preferred route is intramuscular (IM) in the deltoid muscle; 
however, the vastus lateralis muscle is an alternative site (CDC, 2021a).  
 
Tetanus, Diphtheria, Pertussis  
Following receipt of one dose of tetanus, diphtheria, pertussis (Tdap) at age 11 years or 
older, Tdap or tetanus and diphtheria (Td) vaccination is recommended every 10 years or when 
indicated for wound management or pregnancy (Havers et al, 2020). Vaccination prevents the 
spread of life-threatening illnesses to children and in the case of tetanus, a disease that causes 
muscle spasms throughout the body sometimes leading to respiratory arrest. Tdap should be 
administered during gestational weeks 27-36 of each pregnancy. For minor wound management, 
administer Tdap or Td if more than 10 years since the last vaccination. For all other wounds, 
administer Tdap or Td if more than five years since the last vaccination (Havers et al., 2020). The 
preferred route is IM in the deltoid (CDC, 2021a).  
 
Measles, Mumps, Rubella  
All adults who do not have evidence of immunity should receive at least one dose of the 
measles, mumps, and rubella (MMR) vaccine (CDC, 2021a). Vaccination prevents the spread of 
highly contagious infections, which can be especially harmful when spread to children. Students 
attending postsecondary schools, health care workers, and international travelers should ensure 
receipt of at least two doses of MMR. Human Immunodeficiency virus (HIV) positive individuals 
with no evidence of immunity and cluster of differentiation 4 (CD4) count of 200 cells/mm3 or 
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greater for at least six months should also receive the two-dose series. If the second dose is 
indicated, a minimum of 28 days is required between the two-dose series. Evidence of immunity 
includes written documentation of appropriate vaccination, laboratory evidence of immunity, or 
birth before the year 1957. Verbal report of vaccination or disease is not acceptable evidence of 
immunity. Individuals who have been exposed to measles and do not have evidence of immunity 
should be offered post-exposure prophylaxis by administration of MMR vaccine within 72 hours 
of exposure or immunoglobulin (IG) within 6 days of exposure. Contraindications to MMR 
vaccination include pregnancy and severely immunocompromised individuals including HIV 
infection with CD4 count less than 200 cells/mm3. The preferred route is subcutaneous in the 
posterior triceps of the upper arm (CDC, 2021a).  
 
Varicella 
The CDC (2021a) recommends all adults receive 2 doses of the varicella (chickenpox) 
vaccine approximately 4-8 weeks apart. While usually mild in children, unvaccinated adults 
exposed to varicella are more likely to experience serious complications. Contraindications to the 
varicella vaccine include pregnancy and other severely immunocompromised individuals 
including HIV positive with a CD4 count less than 200 cells/mm3. HIV positive individuals with 
CD4 count greater than 200 cells/mm3 may consider vaccination with 2 doses scheduled 3 months 
apart after discussion with their health care provider. The preferred route is IM in the deltoid 





Haughtigan and Groves: Adult Vaccinations
Published by TopSCHOLAR®, 2021
Zoster  
Herpes zoster (shingles) vaccination is recommended for adults 50 years and older 
including those with a history of herpes zoster or previous live zoster vaccine with VZL (Zostavax) 
(CDC, 2021a). RZV (Shingrix) is the only zoster vaccine currently being sold and administered in 
the U.S. and is a non-live, recombinant vaccine consisting of 2 doses scheduled 2-6 months apart. 
Herpes zoster can lead to permanent problems including continued nerve-pain at the site of the 
rash, vision loss, skin infections, and other neurologic problems (Mayo Clinic, 2021). Pregnant 
women should consult with their health care provider and consider delaying vaccination until after 
pregnancy. Severely compromised individuals including those with HIV and CD4 count less than 
200 cells/mm3 should consult with their health care provider as there are currently no vaccination 




 Human papillomavirus (HPV) vaccination is recommended for all adults through age 26 
years and includes a three-dose series for persons receiving their initial vaccination (Meites et al., 
2019). The first dose is followed by a second dose at 1-2 months with the 3rd dose scheduled 6 
months later. Individuals who have less than 5 months between dose one and three, should repeat 
the 3rd dose. If interrupted, the series does not need to be restarted but can safely be resumed with 
no additional doses recommended. The vaccine is designed to prevent new infections and cancers 
such as cervical, anal, penile, vaginal, vulvar, and oropharyngeal (Meites et al., 2019). 
Administration of the HPV vaccine series for adults ages 27-45 years is determined through shared 
decision making between the individual and their health care provider. Vaccination with HPV is 
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contraindicated during pregnancy; however, breastfeeding women may receive the vaccine 
(Meites et al., 2019). The preferred route is IM in the deltoid muscle (CDC, 2021a).  
 
Pneumococcal 
Vaccination against pneumococcal disease, or pneumonia, is recommended for all adults 
65 years and older (Matanock et al., 2019). Pneumonia is a leading cause of hospital admissions, 
meningitis, blood infections, and sepsis (CDC, 2020). In the U.S., 13-valent pneumococcal 
conjugate vaccine (PCV13) and 23-valent pneumococcal polysaccharide vaccine (PPSV23) are 
the only two pneumonia vaccines available. For adults 65 years and over, ACIP recommends a 
one-time dose of PPSV23. Administration of PCV13 is no longer routinely recommended for this 
age group. Shared clinical decision making by the health care provider and individuals 65 years 
and older who are immunocompromised, have cerebrospinal fluid leak, or cochlear implant and 
have never received PCV13, can be utilized to determine if PCV13 should be administered prior 
to PPSV23. At least 1 year should be allowed between administration of PCV13 and PPSV23. 
Adults 65 years and older who received PPSV23 before the age of 65, should receive another 
single dose of PPSV23 at least 5 years from the prior vaccination (Matanock et al., 2019). Adults 
ages 19-64 who smoke cigarettes or have chronic medical conditions such as heart disease, 
diabetes, lung disease, or alcoholism, should receive one dose of PPSV23 (CDC, 2021a). 
Immunocompromised adults 19 years and older should receive one dose of PCV13, followed by 
one dose of PPSV23 a minimum of eight weeks later and then repeated at 5 years. PCV13 or 
PPSV23 can be administered during the same visit of influenza vaccination with different injection 
sites preferred. The favored method of administration of pneumococcal vaccination is IM in the 
deltoid muscle (CDC, 2021a).  
17
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Hepatitis A 
Hepatitis A (HepA) vaccination is recommended by the ACIP for any adult at increased 
risk for hepatitis A viral (HAV) infection, at risk for developing severe illness from HAV infection, 
or any adult who would like protection from this disease regardless of risk (Nelson et al., 2020). 
HepA vaccination is a 2 or 3-dose series administered over 6 to 12 months depending upon the 
specific vaccine. Illegal drug abusers or those in rehabilitation facilities, developmentally delayed 
persons attending day care facilities, persons experiencing homelessness, those with increased 
occupational risk, and international travelers to areas with elevated HAV transmission are 
considered at increased risk for contracting HAV. Severely immunocompromised individuals with 
HIV or chronic liver disease, such as cirrhosis, hepatitis B or C viral infection, or fatty liver disease, 
are considered at risk for development of severe illness from HAV infection and should be 
vaccinated. Severely immunosuppressed individuals should have serologic testing at least 4 weeks 
following completion of the vaccination series to confirm seroconversion and protection. In 
addition, vaccination is recommended for pregnant women who have increased risks of contracting 
HAV or severe outcomes. HepA vaccination is recommended by ACIP for postexposure 
prophylaxis for those with increased risks (Nelson et al, 2020). IM in the deltoid is the preferred 
administration route and site (CDC, 2021a).  
 
Hepatitis B 
Hepatitis B (HepB) vaccination is recommended for all adults at risk for Hepatitis B viral 
(HBV) infection, severe outcomes from HBV infection, or anyone who wishes to be protected 
from HBV. The HepB vaccine is administered as a 2 or 3-dose series with dosing intervals varying 
by manufacturer. HepB vaccination is an important tool for primary prevention of HBV which can 
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become a chronic disease resulting in decreased liver function (Schillie et al., 2018). Chronic liver 
disease, intravenous (IV) drug abuse, close contact with someone infected with HBV, 
hemodialysis, international travel to areas with high HBV transmission, immunosuppression, risk 
for exposure to blood, and diabetes are all considered risks for HBV infection. Pregnant women 
considered at risk for HBV infection should be vaccinated and educated on methods to avoid HBV 
exposure. Postexposure prophylaxis for individuals exposed to HBV through contact with blood 
depend upon HepB vaccination status. Individuals who have completed a HepB series without 
serological testing postvaccination should receive one dose of HepB vaccine. Persons who have 
incomplete vaccination series should receive one dose of hepatitis B immune globulin (HBIG) and 
complete the HepB vaccine series. Completely unvaccinated persons should receive both HBIG 
and HepB vaccine as soon as possible (Schillie et al, 2018). The preferred administration is IM in 
the deltoid muscle (CDC, 2021a). 
 
Meningococcal  
Adults at increased risk for meningococcal disease are recommended to receive vaccination 
against this illness which is caused by the Neisseria meningitidis bacteria (Mbaeyi et al., 2020). N. 
meningitidis can progress to death in a matter of hours or leave survivors with serious long-term 
effects such as loss of limb(s), loss of hearing, or damage to the nervous system (CDC, 2019b). 
There are currently two types of meningococcal vaccines approved for use in the U.S. including 
quadrivalent (serogroup A,C,W, and Y) meningococcal conjugate (MenACWY) and monovalent 
serogroup B meningococcal (MenB) (Mbaeyi et al., 2020). Specific vaccine type and the number 
of doses to administer depends upon which serogroups are most predominant in the location, age, 
and risk factors. For most healthy young adults up to age 23, routine vaccination with MenB is 
19
Haughtigan and Groves: Adult Vaccinations
Published by TopSCHOLAR®, 2021
recommended. Adults at risk due to asplenia or complement component deficiency receiving a 
complement inhibitor, such as eculizumab or ravulizumab, should receive vaccination with both 
MenACWY and MenB. Individuals with HIV are recommended to receive MenACWY and would 
only receive MenB if indicated (age 16-23 years with shared decision making). Persons traveling 
in areas with high rates of meningococcal disease, first year college students living in a residence 
hall if not previously vaccinated at age 16 or older, and military recruits should receive a single 
dose of the MenACWY vaccine. ACIP recommends meningococcal boosters every five years for 
previously vaccinated individuals who remain at risk (Mbaeyi et al., 2020). Pregnant women who 
are at increased risk for meningococcal disease may receive either MenACWY or MenB following 
consultation with their health care provider (CDC, 2021a). The preferred site of administration is 
IM in the deltoid muscle (CDC, 2021a).  
 
Haemophilus Influenzae type b 
Haemophilus Influenzae type b (Hib) vaccination is only recommended for adults with 
certain health conditions to prevent infections leading to problems such as pneumonia, meningitis, 
and sepsis (CDC, 2021a). Adults with asplenia should receive one dose if they previously did not 
receive the Hib vaccine. All individuals who have undergone bone marrow transplant should 
receive a 3-dose series separated by 4 weeks beginning 6-12 months post-transplant. The preferred 
administration is IM in the deltoid muscle (CDC, 2021a).  
 
COVID-19 
In addition to the vaccinations in Figure 1 and Figure 2, COVID-19 vaccination is currently 
recommended for all adults within the scope of Emergency Use Authorization (EUA) for each 
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specific vaccine (CDC, 2021b). There are three vaccine products available in the U.S. including 
Moderna, Pfizer-BioNTech, and Johnson & Johnson (CDC, 2021c). Johnson & Johnson (J&J) is 
a single dose vaccine while Moderna and Pfizer-BioNTech are mRNA products and require 2 
doses recommended at 28 days apart for Moderna and 21 days apart for Pfizer-BioNTech. 
Moderna and Pfizer vaccines allow for a 4-day early vaccination grace period and a delay of up to 
6 weeks for the second dose. If the second dose is administered after 6 weeks, do not restart the 
series. COVID-19 vaccines are not interchangeable, and the product received for the first dose 
should be determined. However, if the first dose product cannot be identified, any available mRNA 
vaccine may be given with a minimum of 28 days between the first and second dose. If an 
individual is unable to receive the second dose of an mRNA product due to a reaction or 
contraindication, a single dose of the J&J vaccine may be administered at a minimum of 28 days 
following the first injection (CDC, 2021c).  
After a short pause on the use of the J&J vaccine in April 2021 due to reports of thrombosis 
with thrombocytopenia syndrome (TTS) in some recipients, the AICP reaffirmed its 
recommendation for use and concluded the benefits of the vaccine outweighed the risks (MacNeil 
et al., 2021). The J&J vaccine now carries a warning for rare thrombotic events primarily among 
women ages 18-49 years. Patient and health care provider education regarding risks, availability 
of alternative vaccine products, and recognition of clinical presentation of TTS symptoms are 
important to guide decision making and treatment. TTS involves acute venous or arterial 
thrombosis along with thrombocytopenia in individuals who have not recently received Heparin. 
Patients should be educated to monitor for and seek immediate medical care for symptoms of blood 
clots with development of thrombocytopenia for approximately 3 weeks following the J&J 
vaccination. Treatment and presentation of TTS is similar to the rare Heparin allergy of Heparin 
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Induced Thrombocytopenia (HIT). Individuals presenting with TTS symptoms should not be 
treated with Heparin, a traditional treatment for thrombotic events, and a hematology specialist 
should be consulted. The resumption of the J&J single dose vaccine provides flexibility and 
improved access for many Americans (MacNeil et al., 2021). 
In June 2021, the ACIP met to review reported cases of myocarditis in primarily young 
males aged 12-29 years occurring a few days after receiving the second dose of the mRNA 
Moderna or Pfizer COVID-19 vaccine (Gargano et al., 2021). The AICP concluded the benefits of 
decreased morbidity and mortality from the vaccines far outweighed the risks of myocarditis and 
continue to recommend the use of mRNA vaccinations. The EUA for mRNA vaccinations has 
been updated with additional information on myocarditis. Patients and health care providers should 
be educated regarding the risks and symptoms of myocarditis to improve early recognition and 
treatment. Symptoms may include dyspnea, angina, palpitations, or syncope. Troponin levels may 
be elevated, and there could be abnormal findings on electrocardiogram or echocardiogram 
consistent with myocarditis. Supportive therapy and exercise restriction are the primary treatment 
recommendations with the need for additional cardiac medications determined on an individual 
basis. Data regarding the incidence of myocarditis will continue to be closely monitored and 
evaluated for any changes in vaccination recommendations. The mRNA vaccines are important 
and safe instruments for the prevention of COVID-19 and associated hospitalizations, disease 
sequela, and deaths for all ages.  
Intramuscular injection in the deltoid muscle is the recommended site and route for all 
COVID-19 vaccine products (CDC, 2021c). COVID-19 vaccines may be administered on the same 
day as other recommended vaccinations. If administering additional vaccines in the deltoid, 
separate injection sites by at least 1 inch. Separate limbs are recommended if additional 
22
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vaccinations frequently result in local reaction. If the deltoid muscle cannot be used, the vastus 
lateralis muscle is an alternate location for injection (CDC, 2021c). 
 
Educational Resources 
Detailed vaccination schedules and recommendations for all ages, underlying conditions, 
travel, and special situations can be found on the CDC website for vaccinations and immunizations 
at: 
https://www.cdc.gov/vaccines/index.html. 
Additional resources for adult immunizations can be found on the U.S. Health and Human Services 
website at: 
https://www.hhs.gov/vaccines/national-adult-immunization-plan/index.html.  
This site contains adult immunization plans and goals for improved physical and organization 
structures and facilities along with access to vaccinations. 
 
Conclusion 
Vaccinations play an important role in lifelong health and wellness by providing protection 
from preventable and potentially deadly infectious diseases such as COVID-19 or influenza. 
Vaccines in the U.S. undergo thorough and ongoing safety and efficacy evaluation before being 
recommended for use by the CDC. This transparent process includes information on 
contraindications, potential adverse effects, and special considerations to help adults and their 
health care providers make informed, best-practice decisions together. As trusted community 
members, FCN can provide accurate and understandable information regarding the safety and 
importance of adult vaccinations leading to improved immunization rates and outcomes. 
23
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